Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy.
Miura K, Takahashi H, Nakagawa M, Izu A, Sugitani M, Kurita D, Sakagami M, Ohtake S, Uchino Y, Hojo A, Kodaira H, Yagi M, Kobayashi Y, Iriyama N, Kobayashi S, Kiso S, Hirabayashi Y, Hatta Y, Takei M.
Miura K, et al. Among authors: izu a.
Leuk Lymphoma. 2016;57(6):1335-41. doi: 10.3109/10428194.2015.1096352. Epub 2015 Oct 22.
Leuk Lymphoma. 2016.
PMID: 26390147